About
Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease.
Retension Pharmaceuticals, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:RTSN
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $11.76 | $11.76 | $10.85 | $11.36 | $11.36 | -0.40 | 58,700 |
| 2026-10-29 | $12.95 | $12.97 | $11.30 | $11.83 | $11.83 | -1.12 | 45,100 |
| 2026-10-28 | $13.44 | $13.90 | $12.19 | $13.09 | $13.09 | -0.35 | 67,300 |
| 2026-10-27 | $14.40 | $14.60 | $12.70 | $13.52 | $13.52 | -0.88 | 75,300 |
| 2026-10-26 | $15.13 | $15.82 | $14.24 | $14.24 | $14.24 | -0.89 | 47,200 |
| 2026-10-23 | $15.85 | $16.29 | $14.59 | $15.25 | $15.25 | -0.60 | 77,900 |
| 2026-10-22 | $14.81 | $16.00 | $14.07 | $15.50 | $15.50 | +0.69 | 121,100 |
| 2026-10-21 | $16.18 | $18.19 | $14.29 | $15.00 | $15.00 | -1.18 | 110,600 |
| 2026-10-20 | $16.53 | $17.40 | $15.11 | $16.18 | $16.18 | -0.35 | 98,300 |
| 2026-10-19 | $14.14 | $18.64 | $14.10 | $16.33 | $16.33 | +2.19 | 267,200 |
| 2026-10-16 | $12.21 | $14.97 | $12.17 | $14.07 | $14.07 | +1.86 | 208,900 |
| 2026-10-15 | $11.56 | $12.86 | $11.56 | $12.21 | $12.21 | +0.65 | 131,000 |
| 2026-10-14 | $11.63 | $12.25 | $11.00 | $11.64 | $11.64 | +0.01 | 77,200 |
| 2026-10-13 | $11.83 | $12.50 | $11.41 | $11.63 | $11.63 | -0.20 | 137,600 |
| 2026-10-12 | $10.88 | $11.79 | $10.16 | $11.32 | $11.32 | +0.44 | 173,900 |
| 2026-10-09 | $10.00 | $11.60 | $9.66 | $10.53 | $10.53 | +0.53 | 789,200 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 8-K | Oct 23, 2026 | Current Report |
| SCHEDULE 13G | Oct 16, 2026 | Filing |
| SCHEDULE 13G | Oct 16, 2026 | Filing |
| SCHEDULE 13G | Oct 15, 2026 | Filing |
| SCHEDULE 13D | Oct 14, 2026 | Filing |
| S-8 | Oct 13, 2026 | Securities to be offered to employees in employee benefit plans |
| 8-K | Oct 13, 2026 | Current Report |
| 424B4 | Oct 9, 2026 | Prospectus |
| EFFECT | Oct 8, 2026 | Notice of Effectiveness |
| S-1MEF | Oct 8, 2026 | Registration adding securities to prior Form S-1 registration |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Eric Keller, J.D.
Chief Executive Officer and Director
Alex Schwartz
Chief Financial Officer
Paul Sweetnam, Ph.D.
Chief Scientific Officer
Alison D. Schecter, M.D.
Chief Medical Officer
Sabine Bisson, Ph.D.
Chief Operating Officer
Michael Joseph Berendt, Ph.D.
Executive Chairman
Franklin M. Berger
Director
Donald Olds, M.B.A.
Director
